Fidaxomicin therapy in critically ill patients with Clostridium difficile infection

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 3, 2015, Pages 1776-1781

  Penziner, Samuel ^a   Dubrovskaya, Yanina ^a   Press, Robert ^a   Safdar, Amar ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CLOSTRIDIUM DIFFICILE TOXIN B; FIDAXOMICIN; MEROPENEM; METRONIDAZOLE; PENICILLIN DERIVATIVE; VANCOMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; GRAFT RECIPIENT; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; LENGTH OF STAY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT RESPONSE; VERY ELDERLY; CLOSTRIDIUM INFECTIONS; CRITICAL ILLNESS; DRUG EFFECTS; HEALTH CARE FACILITY; PEPTOCLOSTRIDIUM DIFFICILE;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CRITICAL ILLNESS; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENTS' ROOMS;

EID: 84923249622     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04268-14     Document Type: Article

References (14)

1. Collini PJ, Bauer M, Kuijper E, Dockrell DH. 2012. Clostridium difficile infection in HIV-seropositive individuals and transplant recipients. J Infect 64:131-147. http://dx.doi.org/10.1016/j.jinf.2011.12.003.
2. Kyne L, Warny M, Qamar A, Kelly CP. 2000. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.N Engl J Med 342:390-397. http://dx.doi.org/10.1056/NEJM2000021034 20604.
3. Kenneally C, Rosini JM, Skrupky LP, Doherty JA, Hollands JM, Martinez E, McKinzie WE, Murphy T, Smith JR, Micek ST, Kollef MH. 2007. Analysis of 30-day mortality for Clostridium difficile-associated disease in the ICU setting. Chest 132:418-424. http://dx.doi.org/10.1378/chest.07-0202.
4. Drekonja DM, Butler M, MacDonald R, Drekonja DM, Butler M, MacDonald R, Bliss D, Filice GA, Rector TS, Wilt TJ. 2011. Comparative effectiveness of Clostridium difficile treatments: a systematic review. Ann Intern Med 155:839-847. http://dx.doi.org/10.7326/0003-4819-155-12-201112200-00007.
5. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK, OPT-80-003 Clinical Study Group. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364:422-431. http://dx.doi.org/10.1056/NEJMoa0910812.
6. Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, Sears P, Gorbach S, OPT-80-004 Clinical Study Group. 2012. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, noninferiority, randomised controlled trial. Lancet Infect Dis 12:281-289. http://dx.doi.org/10.1016/S1473-3099(11)70374-7.
7. Mullane KM, Miller MA, Weiss K, Lentnek A, Golan Y, Sears PS, Shue YK, Louie TJ, Gorbach SL. 2011. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 53:440-447. http://dx.doi.org/10.1093/cid/cir404.
8. Clutter DS, Dubrovskaya Y, Merl MY, Teperman L, Press R, Safdar A. 2013. Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 57: 4501-4505. http://dx.doi.org/10.1128/AAC.01120-13.
9. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH, Society for Healthcare Epidemiology of America, Infectious Diseases Society of America. 2010. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 31:431-455. http://dx.doi.org/10.1086/651706.
10. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. 2007. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45: 302-307. http://dx.doi.org/10.1086/519265.
11. Ziakas PD, Thapa R, Rice LB, Mylonakis E. 2013. Trends and significance of VRE colonization in the ICU: a meta-analysis of published studies. PLoS One 8:e75658. http://dx.doi.org/10.1371/journal.pone.0075658.
12. Al-Nassir WN, Sethi AK, Li Y, Pultz MJ, Riggs MM, Donskey CJ. 2008. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 52:2403-2406. http://dx.doi.org/10.1128/AAC.00090-08.
13. Nerandzic MM, Mullane K, Miller MA, Babakhani F, Donskey CJ. 2012. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis 55(Suppl 2):S121-S126. http://dx.doi.org/10.1093/cid/cis440.
14. Babakhani F, Gomez A, Robert N, Sears P. 2011. Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. Antimicrob Agents Chemother 55:4427-4429. http://dx.doi.org/10.1128/AAC.00104-11.